California CRO WCCT Global Announces New Executive Vice President of Business Development and Marketing, William van Nostrand

090415-2Finished

COSTA MESA, Calif./IReach-PRNewswire/–California CRO WCCT Global announced today the addition of William van Nostrand to their executive management team. Mr. van Nostrand, a pioneer of the CRO industry, will now be serving as WCCT Global’s Executive Vice President of Business Development and Marketing. In the early 1980s, Mr. van Nostrand founded In Vivo, Inc., a global, late phase contract research organization and one of the first CROs in the industry. William van Nostrand brings with him over 40 years of pharmaceutical and clinical research experience.

Prior to serving as the California CRO’s Vice President of Business Development, Mr. van Nostrand held many executive positions including: President of Dendrite International’s Clinical Division, Senior Vice President and GM for the Life Science division of First Consulting Group, and, most recently, Chief Business Officer for the Copernicus IRB. Furthermore, as CEO of his own consulting company, Medical Marketing Solutions, he has assisted many top industry players such as Apple, The Chinese healthy Ministry, GSK, and Allergan with major consulting assignments. Additionally, Mr. van Nostrand has played a key role in multiple M&A deals for several of the companies he has been a part of, both raising capital and selling the company to venture capitalists.

WCCT Global’s Founder and CEO, Kenneth Kim, expressed his thoughts regarding the new addition to the company’s executive management team: “Mr. van Nostrand comes to us with a wealth of both sales and marketing experience as well as a deep domain knowledge of the CRO industry and the key decision makers on both the pharmaceutical and biotechnology side of the business. We are excited to have him on our team and confident of the contributions he will make to the growth of WCCT.” The California CRO is optimistic to see how Mr. van Nostrand will help the company move closer towards its goals both as a company and in making strides in the clinical research industry.